600% Kurspotential YM Biosciences 911799

MISSISSAUGA, ON, Oct. 17 /PRNewswire-FirstCall/ -- YM BioSciences Inc., a company engaged in the acquisition, development and commercialization of oncology and acute care products, today announced results from the open-label portion of its Phase IIb trial (DLXLEF-AP4) of AeroLEF(TM). The results demonstrated that the majority of the patients were able to achieve effective analgesia for episodes of moderate to severe acute post-surgical pain by self-titrating the amount of medication they inhaled using AeroLEF(TM). Results of the study were presented at the American Society of Anesthesiologists (ASA) Annual Meeting in Chicago, IL.

AeroLEF is a unique, inhaled-delivery composition of free and liposome-encapsulated fentanyl, in development for the treatment of moderate to severe pain, including cancer pain. AeroLEF is designed to permit patients to match dosage to their individual pain intensity and experience rapid and extended pain relief.

"The time course of analgesia demonstrated in this study suggest that AeroLEF is suitable for the stabilization of acute post-operative pain," said Sugantha Ganapathy, MD, director, regional anesthesia, Department of Anesthesia and Perioperative Medicine, University of Western Ontario, London, Ontario, Canada, who presented the results. "Furthermore, differences in median times to effective analgesia for patients taking second and third doses of AeroLEF suggests that patients were capable of safely self-limiting dosing to match the intensity of each pain episode."

In the study, patient self-titrated dosing with AeroLEF provided clinically meaningful analgesia in 81 percent, 100 percent and 87.5 percent of treated pain episodes during doses 1, 2 and 3 respectively. Within 10 minutes of initiating dosing with AeroLEF, 38 percent, 73 percent and 63 percent of patients reported a reduction in pain intensity to mild pain during doses 1, 2 and 3 respectively. Achieving effective pain relief was the reason for stopping AeroLEF dosing in 35 of 40 (88 percent) treated pain episodes.

Study results also suggested that multiple doses of AeroLEF were well tolerated. No treatment-emergent adverse events were reported in 9 of 21 (43 percent) of patients. The majority (>70 percent) of treatment-emergent adverse events were mild and considered typical of those associated with opioid analgesia in the post-operative setting. Adverse events of a respiratory nature were reported in 4 patients. These events were mild and transient and resolved with minimal intervention.

"We are pleased that AeroLEF performed well in this open-label portion of our Phase IIb study, providing highly-individualized, episode-specific pain relief in the post-operative setting," said David Allan, Chairman and CEO of YM BioSciences. "We continue to enroll patients in the randomized portion of the trial based on an interim analysis that showed benefit versus placebo."

The Phase IIb of AeroLEF in moderate to severe post-surgical pain consists of two parts. Part I, reported today, was an open label trial designed to allow investigators to gain familiarity with administration of the product. Part I enrolled 21 patients who underwent a variety of elective orthopedic surgical procedures at eight centers. Part II, currently underway, is a randomized, double-blind, and placebo-controlled trial of 99 patients and is designed to evaluate the safety and efficacy of AeroLEF compared to placebo for management of pain following elective orthopedic surgery.

Quelle: PR Newswire  

Weiter so! :-)  

aber das Plus in Frankfurt ist ja noch nicht so überragend!

Und sooo Bahnbrechend sind die Ergebnisse doch auch nicht oder?

Wann kommen denn endlich die News bzgl. Tesmilifene. Dann sollte es doch endlich mal wieder richtig nach oben gehen!  

sind es nicht die absoluten Hammernews, sind ja auch schon seit dem 27.9. bekannt und wurden gestern bei nem Anesthesisten Meeting in Chicago vorgetragen, aber das Mittel wirkt wenn auch villeicht nicht bei jedem, ist nun halt die Frage ob es sich trotzdem lohnt so ein Mittel auf den Markt zu bringen oder bei den alten Analgesiemaßnahmen zu bleiben!? Ich denke aber das es kommen könnte, denn diese Verabreichungsform gibts, soweit ich weiß, noch nicht und kann in gewissen Fällen bestimmt Vorteile gegenüber die anderen Sachen haben!  

Nicht das Du noch den Einstieg verpast! ;-)  

Umsätze stimmen und Kurs geht nun rauf!  

nee, nee, schau gespannt zu. Denke morgen gehts wieder etwas runter - dann schlag ich zu. Und wenn es aufi geht, steig ich auch ein. Galub aber am Nachmittag einen guten Einstiegspunkt zu erwischen, da die Nordamerikaner morgen bestimmt erst mal ihre Gewinne mitnehmen... Bleibe aber dabei, der Chart sieht immer noch nicht positiv aus. Höchstens neutral. Aber auf lane Sicht kann man eigentlich nix falsch machen...  

7,5% bei so einer Nachricht ist ne schöne Quote, da fängt man doch an zu träumen, wenn es richtig gute Nachrichten bezüglich Tesmilifene gibt!  

Oder warum geht der Kurs vorbörslich so deutlich nach oben?
Pre-Market: 3.25  0.26 (8.70%)

Hoffentlich bleibt das dann auch so!  

realistisches Kursziel in 2-3 Jahren sehe ich bei 8€

Und die News war ganz ok :-)
Jetzt mal abwarten wie die Restlichen Produkte bzw. Testphasen laufen...


lg  

In den letzten Tagen war die Performance ja schon sehr positiv, aber heute geht es doch deutlich nach oben! Dabei sind die Umsätze nich extrem hoch...
Gibt es da Gründe für?
Ich habe nix gefunden!
Weiß jemand mehr?

Viele Grüße!  

da scheint auch irgendwas im busch zu sein, aktie zog gestern um 10% an, olaf hordenbach hat den wert in sein musterdepot aufgenommen (bei f.philipps ist er auch drin).
stehen irgendwelche ergebnisse an???
auf jedem fall hochinteressant!!!!!!!!!!!  

YM Biosciences reports first quarter 2007 operational and financial results
   MISSISSAUGA, ON, Nov. 10 /CNW/ - YM BioSciences Inc. (AMEX:YMI, TSX:YM,
AIM:YMBA), an oncology company that identifies, develops and commercializes
differentiated products for patients worldwide, today reported operational and
financial results for the first quarter of fiscal 2007, ended September 30,
2006.
   "Our pivotal Phase III trial for tesmilifene is nearing completion, with
the third of a number of interim analyses anticipated shortly. We continue to
expect the complete set of mature data for our lead anti-cancer drug will be
available in calendar 2007," said David Allan, Chairman and CEO of
YM BioSciences. "For Nimotuzumab we were pleased to report that, during the
quarter, the Office of Foreign Assets Control (OFAC) of the U.S. Treasury
Department issued us a license that allows YM to import nimotuzumab into the
U.S. for the purpose of a clinical trial in children with inoperable brain
cancer. The OFAC license is a key achievement in our efforts to make
nimotuzumab available in the U.S. while we concurrently advance the drug
through a broad multi-national development program internationally with
numerous partners."
   "We also made progress in the development of AeroLEF(TM), our unique,
inhaled-delivery composition of free and liposome encapsulated fentanyl for
the treatment of moderate to severe acute pain, including cancer pain," added
David Allan. "Recently presented results of the open-label portion of our
Phase IIb study demonstrated that patients are able to successfully
self-titrate AeroLEF(TM) for managing acute pain and we intend to further
expand the product's clinical development into patients with cancer pain."

   <<
   Highlights for the first quarter (July 1, 2006 - September 30, 2006):

   Tesmilifene:
   -   The independent Data Safety Monitoring Board (DSMB) made its second
       recommendation that the tesmilifene pivotal trial proceed as planned.
       The Company believes that this demonstrates that the product
       continues to be safe and indicates that the data have the prospect of
       becoming positive as they mature.

   Nimotuzumab:
   -   Received clearance from OFAC to import nimotuzumab for specific
       clinical research in the U.S.
   -   Licensed the drug to Daiichi Pharmaceutical Co., Ltd., a wholly owned
       subsidiary of Daiichi Sankyo Company, Limited, for Japan.
   -   Enrollment of patients in a Phase III trial in pediatric glioma in
       Europe continues by YM partner Oncoscience AG and recruitment is
       expected to be completed in the first half of calendar 2007.
   -   A multi-center Phase I/II trial comparing the effects of the
       combination of nimotuzumab with radiation against radiation alone in
       patients with non-small-cell lung cancer (NSCLC) unfit for
       chemotherapy is also underway, with recruitment anticipated to be
       completed by the end of 2007, or early 2008. This trial is being
       conducted by YM and is expected to be expanded into South Korea
       through YM partner Kuhnil Pharmaceutical Company of Seoul, Korea.

   AeroLEF(TM):
   -   Results of the open-label portion of the Phase IIb study with
       AeroLEF(TM) for the treatment of moderate to severe acute pain in
       post-surgical patients were presented at the American Society of
       Anesthesiologists Annual Meeting in October 2006. The data
       demonstrated that clinically meaningful analgesia was achieved in
       81%, 100% and 87.5% of treated pain episodes during doses 1, 2 and 3
       respectively in the multi-dose study. Differences in median time to
       effective analgesia, with shorter dosing times for doses 2 and 3,
       suggests that patients were capable of safely self-limiting dosing to
       uniquely match each distinct pain episode. Achievement of effective
       analgesia was the reason for patients stopping dosing in 88% of
       treated pain episodes. Multiple doses were well tolerated with all
       treatment emergent events reported at mild ((greater than)70%) or
       moderate.
   -   Interim results from the randomized, placebo-controlled portion of
       Phase IIb trial were announced. That analysis of data from the first
       67 patients from the trial indicated that AeroLEF(TM) provided
       benefit when comparing the treatment arm to placebo, but not the
       degree of difference that would permit an early stopping. Since the
       study was powered to detect benefit at full recruitment it will
       continue as planned to enroll the original target of 99 randomized
       patients. The full data is anticipated early in calendar 2007.

   Corporate highlights:
   -   YM BioSciences was declared, for the second year in a row, a finalist
       of Canada's Top 10 Life Science Companies Competition subsequent to
       the end of the quarter. In particular, the Company was again declared
       one of Canada's top five Later Stage Companies within the
       competition.
   >>

   Financial Results (CDN dollars)
   Total revenue for the quarter ended September 30, 2006 was $1.7 million
compared to $243,000 for the same period last year. Revenue was generated from
out-licensing agreements and interest income. The increase in licensing
revenue is due to the licenses for nimotuzumab to Innogene Kalbiotech Private
Limited (January 2006) for countries in Southeast Asia and Africa and Daiichi
Pharmaceutical Co., Ltd. (July 2006) for Japan.
   Total operating expenditures for the quarter ended September 30, 2006
were $9.7 million compared to $6.2 million for the same period last year.
General and administrative expenses for the first quarter of the fiscal year
were $1.9 million compared to $1.4 million for the same period in the prior
year. Licensing and product development expenses were $7.9 million for the
first quarter of the fiscal year compared to $4.8 million for the first
quarter of last year. The increases were due mainly to the addition of a
senior management team with the acquisition of Eximias in May and increased
expenditures on nimotuzumab.
   Net loss for the fiscal first quarter was $8.1 million ($0.15 per share)
compared to $5.9 million ($0.15 per share) for the same period last year.
   As at September 30, 2006 the Company had cash, cash equivalents and
short-term deposits totaling $93.9 million and current liabilities of
$1.6 million compared to $88.3 million and $3.7 million respectively at June
30, 2006.
   As at September 30, 2006 the Company had 55,782,023 common shares
outstanding, 2,380,953 common shares held in escrow for contingent additional
payment related to the acquisition of DELEX Therapeutics Inc., and 9,022,277
warrants and 4,790,955 options outstanding.


 

 

Was war denn gestern los?

Hat der kleine Einbruch was mit diesem Ranking von dieser Analystin zu tun?
Weiß jemand wie die YM eingeschätzt hat?  

Das ist bei diesem Wert "normal". Meist geringe Umsätze und da gehts mal schnell 10 % in beide Richtungen.  

YM Biosciences wird in der aktuellen Ausgabe des Aktionärs mit einem Kursziel von 4€ empfohlen. Außerdem steht dort, dass zur Zeit wenig Fantasie in den Titel eingepreist ist.  

das ein paar Nachrichten kommen die mal etwas Fantasie in den Kurs bringen! :-)
Weiß allerdings nicht ob für dieses Jahr noch was aussteht!?
Obwohl mir ein stabiler Kurs lieber ist als ein aufgeblähter Kurs durch irgendwelche Fantasien!  

so bin mal wieder online.

@joeflai:

denke vor Ende des Jahres wird hier nichts mehr passieren. Kurs wird denke ich Ende des Jahres so bei 2,35-2,45 stehen. Und dann schaun was die nächsten Jahre bringen *g*


lg  

Mh, als nichts würde ich das ja nicht gerade bezeichnen! :-(
Ohne erkennbare Gründe gehts abwärts, wollen wir mal hoffen das da nur einige noch etwas Weihnachtsgeld brauchten! :-)  

lass uns mal schaun wo die nächsten Tage hinführen....

dann können wir noch mehr analysieren *g*  

 

Du kennst ja meine Einstiegskurse. Und verkauft wird erst bei über 100%...  

Habe auch noch nachgelegt, ich warte auf die 600 %! :-)  

Guten Morgen,

verfolgt noch jemand von euch das wallstreet-online forum:
http://www.wallstreet-online.de/dyn/community/....2.21&thread_page=32

Da ist von einer Zulassungswahrscheinlichkeit für Tesmilifene von 47% die Rede und auch von Insiderkäufen, zum Beispiel von CEO Allen...

Was halltet ihr von den Äußerungen der Leute da?

Langsam krieg ich Angst um mein Geld, falls Tesmilifene in die Hose geht....